Foreword
References (0)
Cited by (3)
Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy
2017, Molecular Therapy OncolyticsCitation Excerpt :Despite encouraging results, OV monotherapy based exclusively on virus replication-induced oncolysis often does not demonstrate all of these desired qualities, especially when tested against virus-resistant malignancies. Today’s hurdles facing OV therapies remain the same as those described in early6–8 and recent reviews.9,10 Several methods have been developed to increase the anti-cancer activities of OVs.
Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy
2014, Molecular TherapyCitation Excerpt :Viral-mediated oncolysis is a cancer therapy approach with the potential to be more effective and less toxic than current regimes due to the viruses’ selective growth and amplification in tumor cells. To date, OV have proven extremely safe in patients, but have generally fallen short of their expected therapeutic value as monotherapies.17,18 The immune-mediated clearance of the virus is considered to be a significant hindrance to the action of OV and therefore we proposed to develop a new approach combining biotherapeutics to improve efficacy of the OV, and in particular, intratumoral spread.
Pro-oncogenic cell signaling machinery as a target for oncolytic viruses
2012, Current Pharmaceutical Biotechnology